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The aim of the study was to investigate the increase in myocar-
dial 99mTc-methoxyisobutylisonitrile (sestamibi) retention in hu-
mans during pharmacologic vasodilation. Methods: For calcu-
lation of the increase in 99mTc-sestamibi retention during
hyperemia, baseline and adenosine triphosphate (ATP)–induced
hyperemic stress sestamibi studies were performed using a
same-day rest–stress protocol. On the injection of sestamibi,
left ventricular dynamic data were obtained for 90 s. The in-
crease in sestamibi retention from baseline to hyperemia was








where Cmh(t) and Cmb(t) are myocardial counts on the tomo-
graphic image, and Cbb(t) and Cbh(t) are the left ventricular
blood-pool counts during the first transit of sestamibi at base-
line and during hyperemia, respectively. Coronary flow increase
during intravenous ATP stress was measured using intracoro-
nary Doppler flow guide wire and compared with the scinti-
graphic results of 28 measurements in 22 patients. Results:
Sestamibi retention increased as coronary flow velocity in-
creased but plateaued at .2.5–3 times baseline flow velocity.
The relationship between the increase in sestamibi retention (Y)
and the increase in flow (X) is expressed as follows: Y 5 0.44 1
0.60X 2 0.068X2 (r 5 0.82). Conclusion: In humans, the in-
crease in 99mTc-sestamibi myocardial retention underestimates
coronary flow reserve, particularly at high flow rates. Knowledge
of these tracer retention characteristics will contribute to a more
comprehensive understanding of the manner and interpretation
of stress sestamibi imaging.
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For assessment of the functional severity of coronary
artery stenosis, scintigraphic approaches with tomographic
or planar imaging technique using perfusion tracers are
performed most frequently. Diagnostic imaging will likely
need to be performed with exercise or pharmacologic vaso-
dilator stress to detect stress-induced ischemia or coronary
flow reserve abnormality, because even significant coronary
artery stenosis is not functionally severe enough to produce
resting myocardial ischemia. The success of pharmacologic
stress myocardial perfusion imaging relies on the ability of
a tracer to accumulate in the myocardial tissue in proportion
to the rate of coronary blood flow disparity induced by the
pharmacologic stressor.
The radiopharmaceutical 99mTc-methoxyisobutylisonitrile
(sestamibi) has been used widely in pharmacologic hyper-
emic stress myocardial scintigraphy as an alternative to
201Tl for noninvasive detection and prognostic assessment
of coronary artery disease (CAD) (1–8). The ability of a
tracer to accumulate in tissue as a function of delivery is
represented by the absolute tissue retention of the tracer. In
the clinical setting, the relationship between the retention of
the tracer and myocardial blood flow is more pertinent. This
relationship defines the accuracy of the tracer to figure
myocardial blood flow over a wide flow range. In canine
experimental models, when sestamibi is administered under
basal conditions, it distributes in the myocardium in pro-
portion to regional myocardial blood flow, but during aden-
osine or dipyridamole stress its uptake plateaus with flow
rates .2–2.5 times normal flow, resulting in an underesti-
mation of high coronary flow rate (9–12). However, the
results of animal experimental study are not always true in
humans (13). Although a few human studies have reported
a comparison of relative sestamibi uptake with myocardial
blood flow measured by positron emission CT (14) or flow
reserve measured by intracoronary Doppler flow guide wire
(3), to our knowledge, no studies have been reported on the
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ability of sestamibi to accumulate in myocardial tissue
during hyperemia in humans.
Accordingly, the goal of this study was to define the
relationship between the increase in regional myocardial
sestamibi retention and the increase in coronary blood flow
velocity measured by intracoronary Doppler flow guide
wire (Flowire; Cardiometrics, Inc., Mountain View, CA)
during adenosine triphosphate (ATP)–induced hyperemia in
patients with suspected CAD.
MATERIALS AND METHODS
Patients
The study population consisted of 22 patients (15 men, 7
women; mean age, 65 6 9.0 y) who were referred for scintigraphic
study because of suspected CAD. Ten patients had a previous
myocardial infarction. Fifteen patients had 1-vessel CAD, 4 pa-
tients had 2-vessel CAD, 1 patient had 3-vessel CAD, and 2
patients had no significant coronary artery stenosis. Previous cor-
onary revascularization had been performed by angioplasty on 13
patients. A total of 28 measurements of coronary flow velocity by
Doppler Flowire performed within a week of the sestamibi myo-
cardial perfusion scintigraphy were included in this study and
analyzed. No clinical events or changes in medications occurred
between the sestamibi studies and the Doppler Flowire measure-
ments. The hospital review board approved the study protocol, and
all patients gave informed consent.
Coronary Flow Velocity Reserve Measurement by
Doppler Flowire
Coronary flow velocity measurements were performed with a
0.356-mm (0.014-in.) Doppler Flowire. After diagnostic angiog-
raphy, the Doppler wire was placed in the target vessel or posi-
tioned .2 cm distal to the stenosis when significant stenosis
existed. After baseline average peak velocity (APV) measurement,
hyperemic APV was recorded during 3–5 min after initiation of the
5-min continuous intravenous ATP injection at a rate of 0.16
mg/kg/min (15,16). Coronary flow velocity reserve (CFR) was
calculated as the hyperemic-to-basal APV ratio. No vessels sub-
tended by collateral flow or a bypass graft were studied.
Measurement of Increase in Absolute 99mTc-Sestamibi
Myocardial Retention
Absolute tracer retention can be calculated in a manner de-





where R is the absolute retention (mL/min/g) of the tracer (t), Ct
is the radioactivity of the tracer in the myocardium (counts per




Ca~t!dt is the time integral of Ca.
The myocardial count on the SPECT image (Cm) can be ex-
pressed as k1Ct and the arterial count (Cb) on the radionuclide
angiogram can be expressed as k2Ca, where k1 and k2 are the
correction factors for the counting rate from the myocardium and
the left ventricular blood pool, respectively, including attenuation






The change in sestamibi retention from baseline (Rb) to during
the hyperemic response (Rh) is expressed as a ratio of the absolute
sestamibi retention during hyperemia to that of baseline (retention
increase ratio [RIR]). The correction factors of k1 and k2 are
considered to be the same at both baseline and hyperemia. There-










where subscripts b and h indicate baseline and hyperemic status,
respectively.
99mTc-Sestamibi Imaging Protocol and Data Analysis
99mTc-sestamibi angiography and SPECT were performed using
a same-day rest–stress imaging protocol (Fig. 1). At rest, just after
the bolus injection of 300–370 MBq 99mTc-sestamibi into the right
medial antecubital vein followed by flushing with 20 mL saline,
first-pass radionuclide angiographic data were obtained from the
anterior view every second for 90 s using a large-field-of-view
gamma camera equipped with a high-resolution, parallel-hole col-
limator. Planar imaging was performed for 1 min with the patient
in the same position 5 min after the radionuclide angiography.
Energy discrimination was centered on 140 keV with a 20%
window, and data were acquired with 64 3 64 matrices with a 1.5
zoom mode. Forty minutes later, SPECT was performed with a
triple-head gamma camera SPECT system equipped with high-
FIGURE 1. Study protocol of rest–ATP
stress 99mTc-sestamibi myocardial scintig-
raphy.
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resolution, parallel-hole collimators (model 9300A; Toshiba, To-
kyo, Japan). The energy discrimination was centered on 140 keV
with a 20% window, and a total of 60 projection images were
obtained in a 64 3 64 matrix over 360°, with 30 s per view.
Tomographic images were reconstructed using a ramp filter with a
Butterworth filter (order, 8; cutoff frequency, 0.53 cycle/cm).
Attenuation correction was not performed.
ATP stress was started immediately after the baseline 99mTc-
sestamibi SPECT. ATP was infused at a rate of 0.16 mg/kg/min for
5 min through the left antecubital vein (15,16). Three minutes after
initiation of the ATP injection, 600–740 MBq 99mTc-sestamibi
were injected through the right medial antecubital vein and flushed
with 20 mL saline. Radionuclide angiographic data were obtained
in the same manner as at the baseline study except that data
acquisition was started 5–10 s before the radionuclide injection to
obtain data for subtraction of the previously injected radionuclide
activity. One hour after the ATP stress, SPECT was performed
again.
First-pass angiographic data were analyzed to obtain the time
integral of the left ventricular first-pass 99mTc-sestamibi counts as
described (17). In brief, on the summed image (3- to 5-s duration)
of the left ventricular phase of the first-pass images, a left ventric-
ular region of interest (ROI) was set by delineating the edge where
the count was 40% of the left ventricular peak count. The aortic
valve plane was delineated manually by detecting a slight narrow-
ing or angulation between the ascending aorta and left ventricle.
When the valve plane was unclear, the anterior image obtained 5
min after the first-pass study was used as a reference. The time
integral of the left ventricular first-pass 99mTc-sestamibi counts was
obtained as an area under the g-variate–fitted left ventricular
time–activity curve derived from the left ventricular ROI. For
measurement of the time integral of the left ventricular first-pass
counts during ATP stress, the same left ventricular ROI was
applied, and curve fitting was performed after subtraction of the
previously injected radionuclide activity.
For quantitative analysis of SPECT images after generation of a
polar map, 20-segment myocardial territories (Fig. 2) subtended by
each of the 3 main coronary arteries (left anterior descending
coronary artery [LAD], left circumflex coronary artery [LCx],
right coronary artery [RCA]) were assigned on the basis of previ-
ous reports of 201Tl SPECT imaging (18,19): segments 1, 2, 7–9,
13–15, 19, and 20 were assigned to the LAD territory, segments 3,
4, 10, and 16 were assigned to the RCA territory, and segments 5,
6, 11, 12, 17, and 18 were assigned to the LCx territory (Fig. 2).
This coronary territory assignment was altered for the lower septal,
lower lateral, and lower apical walls, depending on patterns of
abnormality and coronary anatomy (19). When APV was mea-
sured at the proximal portion of the particular coronary artery, all
assigned segments to the specific coronary artery area were ana-
lyzed. When APV was measured at the middle portion of the
particular coronary artery, basal segments in the assigned area
were excluded from the analysis.
Polar map generation and segmentation of the 20 myocardial
areas were performed automatically using commercially available
software (QGS software; Cedars-Sinai Medical Center, Los An-
geles, CA). The myocardial count in each territory was measured
by averaging all segmental counts in the territory at rest and at
ATP stress. Because 99mTc-sestamibi activity injected at rest re-
mained at stress, the myocardial count at ATP stress in each
territory was obtained by subtracting the decay-corrected resting
count from the count on the second image after ATP stress.
Statistical Analysis
Continuous variables were expressed as mean 6 SD, and he-
modynamic parameters were compared by a paired t test. Sesta-
mibi retention increases in the area with CFR # 2.0, 2.0 , CFR #
3.0, and CFR . 3.0 were compared by ANOVA followed by a
Scheffe test. P , 0.05 was considered statistically significant.
RESULTS
Twenty-eight measurements of CFR by Doppler Flowire
were performed on 22 patients. Doppler flow analysis was
performed 15 times in the LAD, 8 times in the RCA, and 5
times in the LCx. Scintigraphic study and Doppler Flowire
analysis in the LAD were repeated in 2 patients 6 mo later.
Doppler Flowire analysis was performed in 2 coronary
arteries (LAD and LCx in 2 patients, RCA and LCx in 1
patient, LAD and RCA in 1 patient) in 4 patients by repeat-
ing ATP stress on the same day. Doppler Flowire analysis
was performed in 1 coronary artery in the rest of the 16
patients. The radionuclide study was performed first in 11
measurements, and the CFR study was performed first in 17
measurements.
Hemodynamic Response
Hemodynamic data are summarized in Table 1. With
ATP stress, a significant increase in heart rate and a signif-
icant decrease in systolic and diastolic blood pressures were
found in the radionuclide and Doppler Flowire studies.
However, at baseline and at ATP stress, no significant
differences between the radionuclide and Doppler Flowire
studies were found in heart rate and systolic or diastolic
blood pressure.
FIGURE 2. Segmentation of myocardium on polar map gen-
erated from SPECT image. Myocardium is divided into 20 seg-
ments. Hatched, dotted, and white areas are assigned to LAD
territory, LCx territory, and RCA territory, respectively.
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Relationship Between Sestamibi Retention and CFR
In Figure 3, the increase in myocardial retention of 99mTc-
sestamibi during ATP stress was plotted against the corre-
sponding flow velocity increase measured by Doppler Flo-
wire during ATP stress (CFR). As shown, the increase in
myocardial retention of 99mTc-sestamibi plateaued with in-
creasing flow velocity reserve. The solid line in Figure 3 is the
nonlinear curve fit (Y 5 0.44 1 0.60X 2 0.068X2; r 5 0.82)
(20). As shown in Figure 4A, when CFR was ,2.5, the
increase in 99mTc-sestamibi retention and CFR showed a good
linear correlation (Y 5 0.31X 1 0.72; r 5 0.79; P , 0.005),
but the increase in 99mTc-sestamibi retention at higher CFR did
not correlate significantly with CFR (Fig. 4B).
The increase in myocardial retention of 99mTc-sestamibi
with CFR # 2.0 (1.19 6 0.19) was significantly lower than
that with 2.0 , CFR # 3.0 (1.50 6 0.18; P , 0.005) and
CFR . 3.0 (1.78 6 0.18; P , 0.0001). A significant difference
in the increase in 99mTc-sestamibi retention was also found
between CFR .3.0 and 2.0 , CFR #3.0 (P , 0.01).
Relationship Between Coronary Stenosis and CFR and
Increase in 99mTc-Sestamibi Retention
CFR (Fig. 5A) and the increase in myocardial retention of
99mTc-sestamibi (Fig. 5B) are plotted against the percentage
of coronary stenosis. Weak negative linear correlations were
found between the percentage of stenosis and CFR (r 5
0.50; P , 0.01) and the increase in sestamibi retention (r 5




Sestamibi study Doppler Flowire
HR (bpm) SBP (mm Hg) DBP (mm Hg) HR (bpm) SBP (mm Hg) DBP (mm Hg)
Baseline 66 6 13 119 6 19 65 6 8.1 69 6 13 125 6 24 66 6 9.8
ATP stress 75 6 14* 110 6 18* 60 6 11† 76 6 10* 113 6 21† 59 6 11*
*P , 0.0001 compared with corresponding baseline value.
†P , 0.005 compared with corresponding baseline value.
HR 5 heart rate; SBP 5 systolic blood pressure; DBP 5 diastolic blood pressure.
FIGURE 3. Increase in myocardial 99mTc-sestamibi retention
plotted against Doppler Flowire–determined CFR.
FIGURE 4. Increase in myocardial 99mTc-sestamibi retention
vs. Doppler Flowire–determined CFR with ,2.5 (A) and $2.5
(B). Solid (A) and dashed (B) lines indicate regression lines.
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DISCUSSION
This study examined the relationship in humans between
the increase in myocardial sestamibi retention during hy-
peremia and hyperemic CFR measured by Doppler Flowire.
In both measurements, the hyperemia was induced by in-
travenous ATP infusion at the same dose, resulting in a
similar hemodynamic response. This study in humans
showed that the sestamibi retention increased as flow in-
creased, whereas it did not increase proportional to that of
blood flow during hyperemia and plateaued at .2.5- to
3-fold the baseline blood flow, indicating an underestima-
tion of the increase in blood flow by myocardial sestamibi
uptake especially at higher flow rates.
Because the accuracy of scintigraphic detection of ische-
mia depends on the heterogeneity of tracer retention
achieved between normal and ischemic regions encountered
during pharmacologic coronary vasodilation or dynamic
exercise stress, high tracer extraction and retention across
the broad range of myocardial flow are essential character-
istics for an ideal flow tracer. However, as shown in Figure
3, the increase in sestamibi retention was not proportional to
that of blood flow and plateaued at a high increase in flow
rate (.2.5–3 times baseline flow). Although a linear rela-
tionship between sestamibi retention increase and CFR is
observed in the range of CFR ,2.5, the slope of this line
was far from unity (Fig. 4). This curve is characteristic of
any extractable flow tracer such as 201T1 in that the amount
of tracer extracted is limited by flow only at low flow rates
and plateaus at high flow rates, at which the extraction of the
tracer becomes limited by membrane transport. This study
revealed that sestamibi retention kinetics in humans are
similar to those reported in canine experimental models, in
which the initial distribution of sestamibi under basal con-
dition correlated closely with regional blood flow, but when
sestamibi was administered at flow rates .2–3 mL/min/g,
its uptake or retention plateaued (9–12).
For measurement of absolute tracer retention, direct mea-
surement of tissue tracer count (cpm/g) and arterial radio-
activity concentration as an arterial input function (cpm/
mL) is necessary. In this study, the tissue and arterial counts
were measured with a gamma camera; therefore, correction
factors for the counting rate from the myocardium and the
left ventricular blood pool, which are determined primarily
by the attenuation factor, sensitivity of the gamma camera
system, and partial-volume effect, are necessary for the
determination of absolute tracer retention as shown in Equa-
tion 1. These correction factors (k1 and k2) are specific to the
gamma camera system used and the individual patient but
should be unchanged theoretically between imaging at base-
line and at hyperemia. Therefore, they are unnecessary for
calculation of the relative increase in the absolute tracer
retention from baseline to hyperemia because theoretically
they are canceled out. For dynamic data acquisition to
obtain arterial radioactivity concentration, left ventricular
data were used because statistical error should be minimal
(because of a high counting rate) on account of a negligible
count loss associated with the dead time of the gamma
camera and the large sampling volume (17). Dynamic data
acquisition in every second was considered to be adequate
because the time integral of arterial radioactivity during the
first pass of the tracer was quite similar in serial 1- and 0.5-s
acquisitions in a preliminary trial.
Because rest–stress imaging was performed on the same
day, subtraction of the myocardial count of the first image
(rest image) from the second image (ATP stress image) with
consideration of decay correction was necessary to obtain
the true stress myocardial count. Although several conflict-
ing reports regarding the sestamibi kinetics, including re-
distribution after injection in canine and human studies,
FIGURE 5. Relationships between percentage of coronary
stenosis and CFR (A) and increase in myocardial retention of
99mTc-sestamibi (B). Weak negative linear correlations are found
between percentage of stenosis and CFR (r 5 0.50; P , 0.01)
and increase in sestamibi retention (r 5 0.41; P , 0.05). Solid
lines indicate regression lines.
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have been published (10,21–24), the physiologic count
change of sestamibi during rest versus during stress imaging
can be a source of error. To minimize this error, ATP stress
was started just after cessation of the rest imaging, permit-
ting initiation of stress imaging within 1.5 h after rest
imaging; also, .2 times the dose of sestamibi at rest imag-
ing was injected at ATP stress.
The results of this study suggest that it is theoretically
possible for mild to moderate stenosis with less impaired
CFR to be overlooked with sestamibi imaging in conjunc-
tion with vasodilator stress. Although it is not proportional,
sestamibi retention increased as flow increased up to 2.5–3
times baseline and, when CFR #2.0 is considered abnormal
as found in earlier Doppler Flowire studies (3,25–27), the
increase in sestamibi retention with abnormal CFR was
significantly lower than that with normal CFR, suggesting
that sestamibi imaging could differentiate the myocardial
area with abnormal CFR from that with normal CFR. Pre-
vious reports of a comparison between pharmacologic ses-
tamibi stress SPECT imaging and CFR by Doppler Flowire
revealed that coronary stenosis with CFR #2.0 was found in
association with at least 1 reversible sestamibi hypoperfu-
sion defect in all patients, and more reversibly hypoperfused
segments were observed in patients with abnormal CFR
(2.4 6 0.7 segments vs. 0.6 6 1.0 segment; P , 0.05) (3).
Although a significant linear relationship was found be-
tween angiographic coronary stenosis severity and indices
of functional stenosis severity, variability was noted when
either CFR or sestamibi retention increase was plotted
against coronary percentage stenosis. These results are con-
sistent with previous studies that compared CFR with an-
giographic stenosis (3,28).
The approach for evaluation of the relative increase in
sestamibi retention would be useful in assessment of the
global CFR reduction, such as in balanced 3-vessel ische-
mia, hypercholesterolemia, and preclinical atherosclerosis.
(29,30). However, this issue remains to be elucidated.
For measurement of coronary flow reserve (blood flow
increase from baseline to hyperemia), the ratio of hyperemic
to baseline APV was used on the basis of the assumption
that intravenous ATP infusion would not significantly mod-
ify the lumen diameter of major epicardial coronary arteries
(31). Additional methodologic limitations of Doppler as-
sessment of CFR include potential errors associated with
competitive flow in branching or collateral vessels, although
analysis of CFR in the coronary artery with angiographi-
cally documented collateral vessels was excluded from this
study. Angiographically invisible collaterals, coexisting re-
mote CADs, or the presence of infarction might have a
potential confounding effect on CFR measurement.
In this study, the relationship between the increments of
sestamibi retention and coronary flow velocity from base-
line to hyperemia, rather than absolute tracer retention and
coronary flow, was determined. Despite the lack of absolute
tracer retention characteristics versus absolute coronary
blood flow, the ability of the relative increment of tracer
retention against coronary blood flow augmentation should
determine the accuracy of sestamibi as a myocardial perfu-
sion tracer in nuclear cardiac imaging because tracer reten-
tion heterogeneity associated with blood flow heterogeneity
encountered during pharmacologic coronary vasodilation or
physical exercise is the diagnostic determinant of physio-
logically significant coronary artery stenosis. Although
more sophisticated methods for quantification of coronary
vascular bed size based on coronary angiography have been
reported (32), we applied rather simple segmentation to
correlate regional tracer retention and flow data in this
study.
CONCLUSION
In humans, the increase in 99mTc-sestamibi myocardial
retention is not directly proportional to the increase in
coronary flow velocity. Sestamibi retention increases as
flow increases, with significant underestimation and a pla-
teau at .2.5–3 times baseline flow.
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